The US Food and Drug Administration’s controversial recent approval of Alzheimer’s drug Aduhelm has been subject to vociferous criticism from many in the scientific community. Amidst concerns surrounding the drug’s efficacy and price, several expert advisors to the FDA have resigned in protest and…| New Atlas
A new announcement from pharmaceutical company Roche has revealed the failure of a massive global Phase 3 trial testing its latest anti-amyloid Alzheimer's disease treatment. The failure marks another twist in the ongoing rollercoaster of research looking for drugs to reduce build-up of the protein…| New Atlas